---
layout: default
title: Albuterol B P
parent: 僅模型預測 (L5)
nav_order: 49
evidence_level: L5
indication_count: 0
---

# Albuterol B P
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# ALBUTEROL B.P.: Repurposing Evaluation — Insufficient Data for Full Assessment

## One-Sentence Summary

ALBUTEROL B.P. (albuterol per British Pharmacopoeia specification) is a well-known beta-2 adrenergic agonist bronchodilator, widely used internationally for asthma and COPD management.
However, the current Evidence Pack contains **no TxGNN repurposing predictions**, no Singapore regulatory registrations, and no retrievable safety data — meaning a substantive repurposing evaluation cannot be completed at this time.
This report documents the data gaps and recommends a **Hold** decision pending remediation.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in regulatory records |
| Predicted New Indication | No prediction generated |
| TxGNN Prediction Score | N/A — No prediction available |
| Evidence Level | N/A — No supporting evidence retrieved |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | **Hold** |

---

## Clinical Trial Evidence

Currently no related clinical trials registered for this candidate.

> **Note:** Because no TxGNN repurposing target was predicted, no disease-specific trial search was performed.

---

## Literature Evidence

Currently no related literature available for this candidate.

> **Note:** Evidence retrieval requires a predicted indication as a search anchor. No search was executed.

---

## Safety Considerations

Please refer to the package insert for safety information.

> Drug-drug interaction query returned **not found**. Key warnings and contraindications were not retrievable from the current data pipeline. TFDA package insert parsing is listed as a **Blocking** data gap (DG001) and must be resolved before any safety-dependent decisions can be made.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for ALBUTEROL B.P. is critically incomplete — no TxGNN repurposing predictions were generated, the drug carries no Singapore HSA registrations, and both safety data and mechanism of action are flagged as unresolved data gaps. Without a predicted indication, no meaningful repurposing analysis can be conducted.

**To proceed, the following is needed:**

- **[DG001 — Blocking]** Retrieve TFDA/HSA package insert PDF and parse warnings, contraindications, and approved indications
- **[DG002 — High]** Query DrugBank API to obtain mechanism of action (MOA), pharmacological category, and DrugBank ID — the query log shows 1 result was returned but the `drugbank_id` field remains null; confirm and populate this field
- **Re-run TxGNN pipeline** after DrugBank ID is confirmed — the empty `predicted_indications` array indicates the prediction step did not execute or matched no candidates; investigate whether the non-standard suffix "B.P." caused a normalisation failure
- **Confirm drug scope** — verify whether "ALBUTEROL B.P." should be mapped to the INN "salbutamol" (the WHO INN), as HSA/international databases may catalogue this drug under the salbutamol entry, which may explain the zero-registration result
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

